Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Rolling Out8d
What to know about the latest vaccine updates
COVID-19 vaccines target emerging variants, offering improved protection. Learn about their effectiveness, timing, and safety ...
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...
pharmaphorum2d
Novavax begins late-stage trial of COVID-19 vaccine in the UK
It’s one of several agreements with major vaccine makers as the UK hedges its bets over which of the shots will get okayed by regulators first. Novavax’s study is expected to recruit up to ...
Zacks.com on MSN7d
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
U.S. News & World Report5d
Novavax Sees Royalties, Reduced Expenses on COVID Vaccines From Sanofi Partnership
(Reuters) -Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi for COVID-19 vaccines to generate royalties, and reduce ...